These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36231441)

  • 21. Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen.
    Gianotti N; Galli L; Poli A; Torre LD; Vinci C; Carini E; Galli A; Nozza S; Spagnuolo V; Muccini C; Lazzarin A; Castagna A
    AIDS; 2021 Jul; 35(9):1513-1516. PubMed ID: 33831909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Use of Integrase Strand Transfer Inhibitors to Treat HIV in Pregnancy.
    Nissim O; Lazenby GB
    J Midwifery Womens Health; 2021 May; 66(3):403-406. PubMed ID: 34166578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.
    McCoy C; Badowski M; Sherman E; Crutchley R; Smith E; Chastain DB;
    Pharmacotherapy; 2018 Jan; 38(1):86-107. PubMed ID: 29105160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.
    Taramasso L; Lo Caputo S; Magnasco L; Briano F; Poliseno M; Bruno SR; Ferrara S; Pincino R; Sarteschi G; Beltramini S; Sasso E; Mora S; Giacomini M; Bassetti M; Di Biagio A
    AIDS Res Hum Retroviruses; 2022 Jun; 38(6):472-479. PubMed ID: 35172617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Deeks ED
    Drugs; 2018 Jul; 78(10):1013-1024. PubMed ID: 29915897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-tablet regimens in HIV: does it really make a difference?
    Aldir I; Horta A; Serrado M
    Curr Med Res Opin; 2014 Jan; 30(1):89-97. PubMed ID: 24040862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
    Gomez M; Seybold U; Roider J; Härter G; Bogner JR
    Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
    Ogbuagu O
    Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence after treatment switch from a multiple tablet antiretroviral regimen to a single tablet antiretroviral regimen.
    Sutton SS; Magagnoli J; H Cummings T; Hardin JW
    Therapie; 2021; 76(6):567-576. PubMed ID: 33589316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
    Taramasso L; Berruti M; Briano F; Di Biagio A
    AIDS; 2020 May; 34(6):877-881. PubMed ID: 32271252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV.
    Ciccullo A; Baldin G; Putaggio C; Di Giambenedetto S; Borghetti A
    Expert Opin Drug Saf; 2021 Nov; 20(11):1317-1332. PubMed ID: 34018892
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
    Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
    Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between antihypertensive drug use and number of people with high blood pressure in FY 2018: a descriptive epidemiological study based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan open data.
    Mizuno K; Inose R; Yoshimura Y; Muraki Y
    J Pharm Health Care Sci; 2023 Dec; 9(1):47. PubMed ID: 38066634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
    Orkin C; Molina JM; Negredo E; Arribas JR; Gathe J; Eron JJ; Van Landuyt E; Lathouwers E; Hufkens V; Petrovic R; Vanveggel S; Opsomer M;
    Lancet HIV; 2018 Jan; 5(1):e23-e34. PubMed ID: 28993180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
    Margot NA; Wong P; Kulkarni R; White K; Porter D; Abram ME; Callebaut C; Miller MD
    J Infect Dis; 2017 Mar; 215(6):920-927. PubMed ID: 28453836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.
    Gaur AH; Cotton MF; Rodriguez CA; McGrath EJ; Helström E; Liberty A; Natukunda E; Kosalaraksa P; Chokephaibulkit K; Maxwell H; Wong P; Porter D; Majeed S; Yue MS; Graham H; Martin H; Brainard DM; Pikora C
    Lancet Child Adolesc Health; 2021 Sep; 5(9):642-651. PubMed ID: 34302760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
    Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
    Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cost-savings analysis of a candidate universal antiretroviral regimen.
    Ripin D; Prabhu VR
    Curr Opin HIV AIDS; 2017 Jul; 12(4):403-407. PubMed ID: 28383299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.